Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome
Journal of Controlled Release · 2023-08 · 360 · 1-14
DOI: 10.1016/j.jconrel.2023.06.018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-08. Verfasst von Chuanyu Zhuang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, College of Engineering, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul 04763, Republic of Korea. Hauptthemen laut MEDLINE: Acute Lung Injury, COVID-19, Respiratory Distress Syndrome. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) is a devastating inflammatory lung disease with a high mortality rate. ALI/ARDS is induced by various causes, including sepsis, infections, thoracic trauma, and inhalation of toxic reagents. Corona virus infection disease-19 (COVID-19) is also a major cause of ALI/ARDS. ALI/ARDS is characterized by inflammatory injury and increased vascular permeability, resulting in lung edema and hypoxemia. Currently available treatments for ALI/ARDS are limited, but do include mechanical ventilation for gas exchange and treatments supportive of reduction of severe symptoms. Anti-inflammatory drugs such as corticosteroids have been suggested, but their clinical effects are controversial with possible side-effects. Therefore, novel treatment modalities have been developed for ALI/ARDS, including therapeutic nucleic acids. Two classes of therapeutic nucleic acids are in use. The first constitutes knock-in genes for encoding therapeutic proteins such as heme oxygenase-1 (HO-1) and adiponectin (APN) at the site of disease. The other is oligonucleotides such as small interfering RNAs and antisense oligonucleotides for knock-down expression of target genes. Carriers have been developed for efficient delivery for therapeutic nucleic acids into the lungs based on the characteristics of the nucleic acids, administration routes, and targeting cells. In this review, ALI/ARDS gene therapy is discussed mainly in terms of delivery systems. The pathophysiology of ALI/ARDS, therapeutic genes, and their delivery strategies are presented for development of ALI/ARDS gene therapy. The current progress suggests that selected and appropriate delivery systems of therapeutic nucleic acids into the lungs may be useful for the treatment of ALI/ARDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, College of Engineering, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul 04763, Republic of Korea.
- Department of Bioengineering, College of Engineering, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul 04763, Republic of Korea. Electronic address: minhyung@hanyang.ac.kr.
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Zhuang, C., Kang, M., & Lee, M. (2023). Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome. Journal of Controlled Release, 360, 1-14. https://doi.org/10.1016/j.jconrel.2023.06.018
Vancouver
Zhuang C, Kang M, Lee M. Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome. Journal of Controlled Release. 2023;360:1-14. doi:10.1016/j.jconrel.2023.06.018
BibTeX
@article{Zhuang2023,
author = {Zhuang, Chuanyu and Kang, Minji and Lee, Minhyung},
title = {Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome},
journal = {Journal of Controlled Release},
year = {2023},
volume = {360},
pages = {1--14},
doi = {10.1016/j.jconrel.2023.06.018}
}
EUVIMED